Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

doi:10.3748/wjg.v20.i35.12581

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4829)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

423

WORD

239

HTML

3066

Figures (1-4)

111

Tables (1-4)

108

Sum=3947

Sep 21, 2014 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

Masayoshi Yada, Akihide Masumoto, Kenta Motomura, Hirotaka Tajiri, Yusuke Morita, Hideo Suzuki, Takeshi Senju, Toshimasa Koyanagi

Masayoshi Yada, Akihide Masumoto, Kenta Motomura, Hirotaka Tajiri, Yusuke Morita, Hideo Suzuki, Takeshi Senju, Toshimasa Koyanagi, Department of Hepatology, Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan

Author contributions: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T and Koyanagi T designed and performed the research; Yada M analyzed data; Yada M and Masumoto A wrote the paper.

Correspondence to: Akihide Masumoto, MD, PhD, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. amasumotoh1@aih-net.com

Telephone: +81-948-22-3800 Fax: +81-948-29-5744

Received: February 19, 2014
Revised: April 10, 2014
Accepted: June 21, 2014
Published online: September 21, 2014

Core Tip

Core tip: Clinical factors influencing the efficacy of sorafenib for treating patients with advanced hepatocellular carcinoma (HCC) were evaluated in this study. As only the size of the largest tumor correlated significantly with overall survival, analyses were focused on factors affecting time to progression (TTP). Sorafenib was more effective for treating patients with extrahepatic compared to intrahepatic advanced HCC. The occurrence of hand-foot syndrome as an adverse event significantly correlated with increased TTP and may therefore be a useful indicator for adjusting the dose of sorafenib to improve its effectiveness and the health-related quality of life of patients with advanced HCC.